截至14:21，恒生港股通创新药指数上涨0.3%，成分股中，博安生物涨超7%，同源康医药-B涨超4%， 诺诚健华涨超2%，港股通创新药ETF易方达（159316）盘中成交额约5亿元。 华创证券认为，医药行业能在持续经历各种挑战后走向新高最本质的原因，是人类对医药行业的持续需 求和越来越多的未被满足的需求，以及药企不断持续加大研发投入去满足这些需求。中国如今已成为全 球创新药研发的重要参与者，海外授权热度持续连年攀升，医药行业进入"创新驱动"的营收时代。 恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，聚焦港股创新药领军企 业，港股通创新药ETF易方达（159316）为目前市场上唯一跟踪该指数的产品，可助力投资者一键把握 板块投资机会。 消息面上，《广州市加快建设先进制造业强市规划（2024—2035年）》昨日印发。其中提出，加速创新 药物战略布局，大力发展单克隆抗体、疫苗、血液制品、诊断试剂等生物制药。此前，北京、上海、重 庆、西安等多地也出台相关政策，推动创新药行业高质量发展。 ...

智通财经APP获悉，12月31日，恒生指数公司发表《2025年终市场总结报告》。2025年，以恒生指数(恒指)为代表的香港股票市场上升27.8%，为2017年以 来最佳表现。2024年录得17.7%升幅后，除3月底因贸易冲突而有所回落，恒指于2025年大部分时间均稳步向上。2025年升势由多个主要因素组成，包括港 股通创纪录的资金流入、对人工智能未来发展的憧憬，以及降息等。2025年，恒指表现跑赢另外两项旗舰指数—恒生中国企业指数(国指)及恒生科技指数(科 指)，两者分别上涨22.3%及23.5%。值得留意的是，追踪恒生生物科技指数的期货于11月推出，而该指数于2025年上升64.5%。 ESG指数方面，恒生气候变化1.5℃目标指数表现较佳，年度升幅为31.2%。 2025年，恒生综合指数(恒生综指)上涨31.0%。在恒生综指中，中型股上升31.6%，领先大型股(+30.8%)及小型股(+28.8%)。在恒生综指的行业指数中，原材 料业表现最佳，上升161.3%，公用事业则是表现最差的行业，录得5.7%升幅。 香港上市的主题指数方面，恒生港股通创新药指数及恒生医疗保健指数表现最佳，年度升幅分别为64.0%及5 ...

恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，聚焦港股创新药领军企 业，恒生创新药ETF（159316）为目前市场上唯一跟踪该指数的产品，可助力投资者一键把握板块投资 机会。 每日经济新闻 今日早盘，港股创新药板块高开高走，截至11:05，恒生港股通创新药指数上涨2.0%，成份股中，映恩 生物-B涨超7%，乐普生物-B、诺诚健华、三生制药涨超4%，恒生创新药ETF（159316）成交额近4亿 元。 近日，西安市发布《促进生物医药产业能力提升实施方案（2025—2027年）》，其中提到，在干细胞药 物、多肽药物、肝靶向创新药物、麻醉制品等领域突破一批药物研发关键核心技术；支持企业开展Ⅰ类 创新药、临床紧缺药研发及成果转化，推动企业研发立项Ⅱ类创新药。今年以来，北京、上海、重庆、 四川等多地也出台相关政策，推动创新药行业高质量发展。 长江证券指出，医药行业呈现一定的政策周期性。近年来，创新药全产业链支持政策逐步落地，比如引 入保险增量资金、丙类医保目录、临床试验30日审批通道等，医药行业尤其是创新药已经步入新一轮的 政策支持发展新周期。未来，应关注部分优质创新药资产，一是"硬创新"资 ...

Core Viewpoint - The pharmaceutical industry is experiencing fluctuations, with A-share pharmaceutical sector showing collective low-level volatility, while Hong Kong's pharmaceutical sector is seeing wide fluctuations and slight declines, particularly in the innovative drug sub-sector which is showing strength [1] Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.9%, achieving a "four consecutive days of gains" [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 0.01% [1] - The CSI Biotech Theme Index decreased by 0.6%, while both the CSI Innovative Drug Industry Index and the CSI 300 Pharmaceutical and Health Index dropped by 0.7% [1] Group 2: Industry Insights - According to Citic Securities, Chinese pharmaceutical companies account for approximately 30% of the global business development (BD) transaction volume [1] - The characteristics of innovative drug research and development in China are described as "fast, good, economical," making it a significant source for overseas pharmaceutical companies' product introductions [1] - Domestic pharmaceutical companies are transitioning from being demand-side players in innovative drug projects to becoming providers, with BD income becoming an important source of revenue expansion [1]

Core Insights - The Chinese pharmaceutical industry is entering a critical phase characterized by "innovation realization and global expansion," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diversified overseas pathways, with a focus on innovation commercialization, global breakthroughs, policy optimization, and opportunities for industry mergers and acquisitions by 2026 [1] Index Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.9% [1] - The China Securities Hong Kong Stock Connect Medical and Health Comprehensive Index increased by 1.0% [1] - The China Securities Innovative Drug Industry Index decreased by 0.2% [2] - The China Securities Biotechnology Theme Index fell by 0.6% [1] - The CSI 300 Medical and Health Index declined by 0.7% [1] ETF Details - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which focuses on innovative drug companies in Hong Kong [2] - The index consists of no more than 40 stocks involved in innovative drug research, development, and production, with a rolling P/E ratio of 58.2 times [2] - The China Securities Hong Kong Stock Connect Medical and Health Comprehensive Index includes 50 stocks from the medical device, biopharmaceutical, and chemical drug sectors, with a rolling P/E ratio of 28.3 times [2] - The China Securities Innovative Drug Industry Index focuses on A-share innovative drug leaders, comprising no more than 50 stocks, with a rolling P/E ratio of 49.9 times [2] - The China Securities Biotechnology Theme Index includes up to 50 stocks in gene diagnostics, biopharmaceuticals, and blood products, with a rolling P/E ratio of 54.8 times [3] - The CSI 300 Medical and Health Index covers companies in the medical and health sector, with a rolling P/E ratio of 30.7 times [3]

Group 1 - The core viewpoint is that the recent meeting between the US and China leaders has positively impacted the market sentiment towards innovative drugs, leading to significant gains in related stocks and ETFs [1][2] - The Hang Seng Innovative Drug ETF (159316) saw a net inflow of over 1.7 billion yuan in the past 20 days, indicating a clear trend of bottom-fishing by investors [2] - The Hang Seng Innovative Drug Index, which excludes CXO companies, focuses on core enterprises in the innovative drug industry, providing investors with a convenient tool to invest in leading innovative drug companies in Hong Kong [2] Group 2 - The industry fundamentals indicate that 2025 will be a critical year for Chinese innovative drugs going global, with expected patent licensing transaction amounts exceeding 100 billion USD, a 170% year-on-year increase [1] - China has become a significant contributor to the global innovative drug industry, with the proportion of patents acquired by the US from Chinese companies rising from 5% in 2019 to 24% [1]

Core Viewpoint - The innovative drug industry trend remains unchanged, with sufficient adjustments made currently, and it is expected that innovative drugs will rise again after the third quarter reports [1] Group 1: Industry Trends - The CXO sector is performing well, benefiting from potential performance catalysts and high prosperity, with the overseas CXO industry entering a phase of accelerated recovery [1] - There is a clear recovery trend in macro-level BD transactions and mergers and acquisitions, while micro-level new molecular businesses maintain high prosperity [1] - The medical device sector is experiencing a policy turning point, with stock prices, valuations, and allocations at the bottom, and the fundamentals are expected to improve [1] Group 2: Investment Recommendations - It is recommended to focus on innovative drugs, the innovative drug industry chain (export-oriented CXO), and medical devices as the main lines for medium to long-term investment [1] Group 3: ETF Performance - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies on the Sci-Tech Innovation Board, tracking 30 representative quality companies in the Shanghai Stock Exchange Sci-Tech Innovation Drug Index, primarily featuring high-growth biotech [1] - Since the "924 market" last year, the Sci-Tech Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovative Drug Index, with respective gains of 117.04% and 109.62% during the market rebound period from September 24, 2024, to September 30, 2025 [1] - The Sci-Tech Innovation Drug Index may help better share the elasticity of the Sci-Tech Innovation Board when market risk appetite rebounds [1]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a strong performance, with the Hang Seng Innovative Drug Index rising by 1% as of 14:26, indicating positive market sentiment towards Chinese innovative pharmaceutical companies [1] Group 1: Market Performance - The Hang Seng Innovative Drug Index saw a rise of 1%, with notable gains from stocks such as Cloudtop New Drug rising over 5%, and Zai Lab and Four Rings Pharma both increasing over 3% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a net subscription of over 120 million units during the trading session, reflecting strong investor interest [1] Group 2: Industry Developments - At the 2025 European Society for Medical Oncology (ESMO) annual meeting, Chinese innovative drug companies contributed over 440 abstracts, with 32 studies included in the latest breakthrough abstracts, showcasing their research capabilities across multiple cancer types [1] - According to Industrial Securities, the innovative drug sector's favorable conditions are expected to persist, with the "innovation + internationalization" trend remaining a core focus of the pharmaceutical industry [1] Group 3: Investment Opportunities - The innovative drug industry is anticipated to continue receiving policy support, enhancing the global competitiveness of Chinese innovative drugs and ensuring ongoing commercial profitability [1] - The Hang Seng Innovative Drug Index has been designed to exclude CXO, making it the first "pure" innovative drug index with 100% purity, accurately reflecting the overall performance of Chinese innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index in the market, providing investors with a streamlined way to capitalize on opportunities in the innovative drug sector [1]

Core Insights - The trend of Chinese innovative drugs going global is a long-term development, with limited impact from external environmental changes [1] - In the first half of 2025, there were 72 License-out transactions from China, exceeding half of the total transactions in 2024, with a total transaction value 16% higher than that of 2024 [1] - The number of significant business development (BD) deals from listed companies has decreased, and NewCo format BDs have not met market expectations [1] Industry Performance - The China Science and Technology Innovation Drug ETF (GTJA, 589720) focuses on innovative drug companies on the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies [1] - Since the "924 market" rally last year, the Sci-Tech Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovation Drug Index [1] - During the market rebound from September 24, 2024, to October 10, 2025, the Sci-Tech Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index increased by 103.5% and 100.5% respectively [1]

Group 1 - The core viewpoint is that there are several promising directions for technology investment, particularly in AI innovation, humanoid robots, and self-controllable technology in the chip sector [1] - AI capital expenditure is still in its early stages and remains largely conceptual, indicating potential for future growth [1] - The active users in the AI field are noteworthy, with a potential shift from free to paid AI services in the future, which could significantly impact company performance and market growth [1] Group 2 - The innovative drug sector has shown significant performance this year, driven by notable advancements in drug development and resulting changes in company earnings [1] - The innovative drug industry has high financing requirements, and the current macroeconomic environment, characterized by relatively loose global monetary policy, presents a favorable opportunity for growth [1] - The valuation of the Hong Kong innovative drug sector has greater room for improvement, making the Hang Seng Hong Kong Stock Connect Innovative Drug Index a point of interest [1]